The overall objective of this proposal is to define the immunoregulatory role of anti-idiotypic antibodies to anti-HLA. Using a microcytotoxicity inhibition assay, we have recently obtained evidence for development of anti-HLA antibodies followed by anti-idiotypic antibodies to HLA class 1 and 11 antibodies in human liver allograft recipients. The proposed research will define the fine specificities of anti-anti-HLA activity using multiple monospecific anti-HLA reagents in order to determine the extent of idiotypic cross-reactivity that exists between antibodies that define distinct polymorphisms of MHC class 1 and class 11 antigens. In particular, these studies will define the extent to which antibodies directed to cross-reactive HLA epitopes (CREGs) express cross-reactive idiotopes. Our preliminary studies Indicate that these anti-idiotypic antibodies to anti-HLA antibodies bind to autologous stimulated T cell and possibly to the clonotypic T cell structures. We will determine the ability of pre- and post- transplant sera to bind to autologous normal and activated T lymphocytes, including biopsy derived T cell clones, using immunofluorescence and flow cytometry. We will use selected sera which bind to T cells in immunoprecipitation analysis, to define the immunochemical nature of the membrane molecules reactive to the anti-idiotypic antibodies. Since anti-idiotypic antibodies to anti-HLA antibodies are reactive with T cells possibly via T cell clonotypic structures, we will determine the immunoregulatory effects of these antibodies on specific cellular immune functions. We will analyze the capacity of anti-idiotypic antibodies to block mixed lymphocyte culture responses of recipients against donor antigens, to block cytotoxic T lymphocyte generation and killing, and to Inhibit proliferation and/or killing by biopsy derived cloned T lymphocytes. Finally, we will develop methods with which to establish anti-anti-HLA secreting B cells; these will include transformation of B cells secreting antibodies using Epstein-Barr virus and/or fusion with mouse myeloma partners. The long term goal of this study is to further define the role of anti-idiotypic antibodies in the regulation of human immune responses so that idiotypic manipulation of immune response to transplantation and tumor antigens can become a viable goal.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Schools of Medicine
Saint Louis
United States
Zip Code
Chauhan, B; Mathew, J M; Shenoy, S et al. (1995) Donor human leukocyte antigens in the circulation of liver allograft recipients. Clin Transplant 9:14-9
Chauhan, B; Phelan, D L; Marsh, J W et al. (1993) Characterization of antiidiotypic antibodies to donor HLA that develop after liver transplantation. Transplantation 56:443-8
Ratner, L E; Phelan, D; Brunt, E M et al. (1993) Probable antibody-mediated failure of two sequential ABO-compatible hepatic allografts in a single recipient. Transplantation 55:814-9
Mathew, J M; Marsh, J W; Susskind, B et al. (1993) Analysis of T cell responses in liver allograft recipients. Evidence for deletion of donor-specific cytotoxic T cells in the peripheral circulation. J Clin Invest 91:900-6
Duffy, B F; Mathew, J M; Flye, M W et al. (1993) Development of autoantibodies to T cell clonotypic structures in a liver-kidney allograft recipient. Transplantation 56:212-6
Phelan, D; Hadley, G; Duffy, B et al. (1991) Antiidiotypic antibodies to HLA class I alloantibodies in normal individuals: a mechanism of tolerance to noninherited maternal HLA antigens. Hum Immunol 31:1-6
Hadley, G A; Phelan, D; Duffy, B F et al. (1990) Lack of T-cell tolerance of noninherited maternal HLA antigens in normal humans. Hum Immunol 28:373-81